BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 11792760)

  • 1. Maintenance dialysis population dynamics: current trends and long-term implications.
    Lysaght MJ
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S37-40. PubMed ID: 11792760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions.
    Port FK
    Kidney Int Suppl; 1995 Aug; 50():S3-6. PubMed ID: 8544432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Care of undocumented individuals with ESRD: a national survey of US nephrologists.
    Hurley L; Kempe A; Crane LA; Davidson A; Pratte K; Linas S; Dickinson LM; Berl T
    Am J Kidney Dis; 2009 Jun; 53(6):940-9. PubMed ID: 19327878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-stage renal disease in the United States: an update from the United States Renal Data System.
    Foley RN; Collins AJ
    J Am Soc Nephrol; 2007 Oct; 18(10):2644-8. PubMed ID: 17656472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting the number of patients with end-stage renal disease in the United States to the year 2015.
    Gilbertson DT; Liu J; Xue JL; Louis TA; Solid CA; Ebben JP; Collins AJ
    J Am Soc Nephrol; 2005 Dec; 16(12):3736-41. PubMed ID: 16267160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The financial implications for Medicare of greater use of peritoneal dialysis.
    Neil N; Guest S; Wong L; Inglese G; Bhattacharyya SK; Gehr T; Walker DR; Golper T
    Clin Ther; 2009 Apr; 31(4):880-8. PubMed ID: 19446160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of end stage renal disease and implications for public policy.
    Rubin RJ
    Public Health Rep; 1984; 99(5):492-8. PubMed ID: 6435162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing body mass index and obesity in the incident ESRD population.
    Kramer HJ; Saranathan A; Luke A; Durazo-Arvizu RA; Guichan C; Hou S; Cooper R
    J Am Soc Nephrol; 2006 May; 17(5):1453-9. PubMed ID: 16597682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dialysis facility of the future: the financial and social environment.
    Steinman TI
    Semin Nephrol; 1997 Jul; 17(4):298-305. PubMed ID: 9241715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic microangiopathy in United States long-term dialysis patients.
    Perkins RM; Reynolds JC; Ahuja TS; Reid T; Agodoa LY; Bohen EM; Yuan CM; Abbott KC
    Nephrol Dial Transplant; 2006 Jan; 21(1):191-6. PubMed ID: 16204286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.
    Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dean BB; Danese MD; Dubois RW
    Am J Kidney Dis; 2005 Aug; 46(2):301-8. PubMed ID: 16112049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia.
    Prodjosudjadi W
    Ethn Dis; 2006; 16(2 Suppl 2):S2-14-6. PubMed ID: 16774003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The databases: renal replacement therapy since 1989--the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA).
    Zoccali C; Kramer A; Jager K
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S18-22. PubMed ID: 19996000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.